medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2012, Número 2

<< Anterior Siguiente >>

Arch Neurocien 2012; 17 (2)


Nanotecnología y cáncer: aplicación al tratamiento de tumores cerebrales

Alvarez-Lemus, López-Goerne T

Idioma: Español
Referencias bibliográficas: 62
Paginas: 102-109
Archivo PDF: 91.16 Kb.


RESUMEN

La ausencia de un tratamiento efectivo para tumores cerebrales malignos como el glioblastoma multiforme (GBM), motivan a los investigadores a la búsqueda de alternativas que permitan ofrecer una solución que mejore la calidad de vida que además pueda prolongarla. El conocimiento actual sobre los procesos biológicos nos permite un mejor entendimiento de los mismos; así como la oportunidad de poder diseñar tratamientos más efectivos, como los que ofrece la nanotecnología. El diseño de materiales altamente selectivos, representan actualmente la oportunidad de mayor potencial a mediano y largo plazo, para técnicas de diagnóstico temprano y tratamientos selectivos que impacten en la sobrevida y la calidad de la misma, en pacientes con tumores cerebrales malignos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Cancer Repor t 2008. World Health Organization, International Agency for Cancer Research http://www.iarc.fr/ en/publications/pdfs-online/wcr/2008/index.php

  2. Estadísticas a propósito del día mundial contra el cáncer. Datos Nacionales. INEGI

  3. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987; 59:1617-25.

  4. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985; 56:1106- 11.

  5. Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al. Late cognitive and radiographic changes related to radiotherapy- initial prospective findings. National Center for Biotechnology Information 2002; 59:40-8.

  6. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Nat Can Inst 1998; 90(12):889-905.

  7. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. National Center for Biotechnology Information 1998;150(5)146-56.

  8. Dougher ty TJ. An update on photodynamic therapy applications. National Center for Biotechnology Information. J Photochem Photobiol B 2002; 20(1):3-7.

  9. Stummer W, Hassan A, Kempski O, Goetz C. Photodynamic therapy within edematous brain tissue: considerations on sensitizer dose and time point of laser irradiation. J Photochem Photobiol B 1996;36(2):179-81.

  10. Bredel M, Zentner J. Brain-tumour drug resistence: the bare essentials. Lancet Oncol 2002;3(7):397-406.

  11. Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S, et al. Summary version of the standards, options and recommendations for the management of adult patients with intracranial glioma. Br J Cancer 2003;1:73-83.

  12. Stupp R, Mason WP, Van den Beuf MJ. Radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma. New Eng J Med 2005;352(10):987-96.

  13. Terasaki M, Ogo E, Fukushima S, Sakata K, Miyagi N, Abe T, et al. Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. Surgical Neurology 2007; 68 (3):250-4.

  14. Mansouri-Torshizi H, Saeidifar M, Divsalar A, Saboury AA. Interaction studies between a 1,10-phenanthroline adduct of palladium(II) dithiocarbamate anti tumor complex and calf thymus DNA. A synthesis spectral and in-vitro study. Spectrochim. Acta A Mol Biomol Spectrosc 2010;77(1):312-8.

  15. Vujic JM, Cvijovic M, Kaluðeroviæ N, Milovanovic M, Zmejkovski BB, Volarevic, et al. Palladium (II) complexes with R2edda derived ligands. Par t IV. O,O2 -dialkyl esters of (S,S)- ethylenediamine-N,N2 -di-2-(4-methyl)-pentanoic acid dihydrochloride and their palladium(II) complexes: synthesis, characterization and in vitro antitumoral activity against chronic lymphocytic leukemia (CLL) cells. Eur J Med Chem 2010;45:3601-6.

  16. Sönmez M, Celebi M, Yardim Y, Sentürk Z. Palladium (II) and platinum(II) complexes of a symmetric Schiff base derived from 2,6,diformyl-4-methylphenol with N aminopyrimidine: Synthesis, characterization and detection of DNA interaction by voltammetry. Euro J Med Chem 2010;45(9):4215-20.

  17. Boiardi A, Eoli M, Salmaggi A, Lamperti E, Botturi A, Solari A, et al. Local drug deliver y in recurrent malignant gliomas. Neurolodical Sciencies 2005;26:37-9.

  18. Tian W, Ying X, Du J, Guo J, Men Y, Zhang Y, et al. Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats. Eur J Pharmace Sci 2010;41(2):232-43.

  19. Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, et al. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 2008;70(3):259- 67.

  20. Ferrari M. Cancer nanotechnology: oppor tunities and challenges, Nature Reviews. Cancer 2005:5(3):161-71.

  21. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology 2007;2(12)751-60.

  22. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995;41:44-8.

  23. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood–brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995;674:171-4.

  24. Kreuter J. Nanoparticulate systems for brain delivery of drugs, Adv. Drug Delivery Rev 2001;47:65-81.

  25. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007;28(5):869-76.

  26. Yang R, Chen T, Chen H, Wang W. Microfabricaction of biodegradable (PLGA) honeycomb-structures and potential applicactions in implantable drug deliver y. Sensors and Actuators B Chemical 2005;106:506-11.

  27. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al. Interstitial chemotherapy with carmustine loaded polymers for high grade gliomas: a randomized doubleblind study. Neurosurgery 1997; 41(4): 44-8.

  28. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial, Acta Neurochir (Wien) 2006; 148(3):269-75.

  29. Stupp R, Mason WP, Van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New Eng J Med 2005;352:987-96.

  30. Garfield J, McDonald H, Punt J. Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Euro J Cancer 1991;27:568-57.

  31. Muller H, Brock M, Ernst H. Long-term survival and recurrencefree interval in combined surgical, radio and chemotherapy of malignant brain gliomas. Clin Neurol Neurosurg 1985;87:167-71

  32. Lissoni P, Meregalli S, Nosetto L. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996;53:43-6.

  33. Lissoni P, Meregalli S, Fossati V, Barni S, Tancini G, Barigozzi P, et al. Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy. Tumori 1993;79(3):198-201.

  34. Fischer SP, Lindermuth J, Hash C, Shekin HA. Levamisole in the treatment of glioblastoma multiforme. J Surg Oncol 1985; 28:214-6.

  35. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 1994;44(8):1479-83.

  36. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined posoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Surg Neurol 1987;27:259-63.

  37. Moffat BA, Reddy GR, McConville P, Hall DE, Chenevert TL, Kopelman RR, et al. A novel polyacr ylamide magnetic nanoparticle contrast agent for molecular imaging using MRI, Molecular Imaging 2003;2(4):324-32.

  38. Brioschi AM, Calderoni S, Zara GP, Priano L, Gasco MR, Mauro A. Solid lipid nanoparticles for brain tumors therapy: State of the art and novel challenges. Progress in Brain Research 2009;180:193-223.

  39. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Advanced Drug Delivery Reviews 2007;59(6):491-504.

  40. Simeonova M, Velichkova R, Ivanova G, Enchev V, Abrahams I. Poly (butylcyanoacrylate) nanoparticles for topical delivery of 5-fluorouracil. Int J Pharm 2003;263(1-2):133-40.

  41. Sullivan CO, Birkinshaw C. In vitro degradation of insulin-loaded poly (n-butylcyanoacr ylate) nanopar ticles. Biomaterials. 2004;25(18):4375-82.

  42. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, et al. Chemotherapy of brain tumoour using doxorubicin bound to sur factant-coated poly (butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactant. J Control Rel 2007;117:51-8.

  43. Wang CX, Huang LS, Hou LB, Jiang L, Yan ZT, Wang YL, et al. Antitumor ef fects of polysorbate-80 coated gemcitabine polybutylcyanoacr ylate nanopar ticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of brain tumor model. Brain Research 2009;1261:91-9.

  44. Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, et al. Drug delivery to the brain using sur factant-coated poly(lactide-co-glicolide) nanopar ticles: Influence of the formulation paremeters. Eur J Pharma Biopharma 2010;74:157-63.

  45. Menei P, Boisdron-Celle M, Croué A, Guy G, Benoit JP. Effect of Stereotactic Implantation of Biodegradable 5-fluorouracilloaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 1996;39:117-24.

  46. Ranganath SH, Fu Y, Arifin DY, Kee I, Zheng L, Lee HS. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials 2010;31:5199- 207.

  47. Kopelman R, Philbert M, Koo YEL, Moffat BA, Reddy GR, McConville P, et al. Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. J Magn Mater 2005;293:404-10.

  48. Xu H, Buck SM, Kopelman R, Philbert MA, Brasuel M, Ross B. Photoexcitation based nano-explorers: chemical analysis inside live cells and photodynamic therapy. Isr J Chem 2004;44:317-37.

  49. Reddy GR, Bhojani M, McConville PM, Moody J, Moffat BA, Hall DE, et al. Vascular Targeted Nanoparticles for imaging and treatment of brain tumors. Clin Can Resear 2006;12:6677.

  50. López T, Ortiz E, Quintana P, González RD. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain, Colloid. Surf. A. Physicochem Eng Asp 2007;300:3-10.

  51. Markowitz MA, Schoen PE, Kust P, Bruce P. Surface acidity and basicity of functionalized silica particles. Colloids Surf. A: Physicochem. Eng Aspects 1999;150:85-94.

  52. Arcos D, Vallet-Regí M. Sol-gel silica-based biomaterials and bone tissue regeneration. Acta Biomaterialia 2010;6:2874-88.

  53. Oshida Y. Surface modifications, in bioscience and bioengineering of titanium. Materials 2007;11:311-79.

  54. López T, Bosch P, Azomoza M, Gómez R. Ru/SiO2-1mpregnated and Sol-Gel-Prepared Catalysts: Synthesis, Characterization, and Catalytic Properties. J Catalysis 1992;133:247-59.

  55. López T. Silica synthesis via sol-gel with organic acids used as catalysts. React Kinet Catal Lett 1992;46:45-50.

  56. Gómez R, López T, Or tiz-Islas E, Navarrete J, Sánchez E, Tzompanztzi F, et al. Effect of sulfation on the photoactivity of TiO2 sol-gel derived catalysts. J Mol Catal A Chem 2003; 193:217-26.

  57. López T, Manjarrez J, Rembao D, Vinogradova E, Moreno A, González RD. An implantable sol-gel derived titania-silica carrier system for the controlled release of anticonvulsants. Mat Lett 2006;60:2903-8.

  58. López T, Quintana P, Martínez JM, Esquivel D. Stabilization of dopamine in nanosilica sol–gel matrix to be used as a controlled drug delivery system. J Non-Cristal Sol 2007;353:987-9.

  59. Gupta R, Chaudhury NK. Entrapment of biomolecules in sol-gel matrix for applications in biosensors: Problems and future prospects. Biosensors and Bioelectronics 2007;22: 2387-99.

  60. Böttcher H, Slowik P, Süb W. Sol-gel Carrier Systems for Controlled Drug Delivery. J Sol-gel Sci Technol 1998;13:277- 81.

  61. López T, Recillas S, Guevara P, Sotelo J, Álvarez M, Odriozola JA. Pt/TiO2 brain biocompatible nanoparticles: GBM treatment using the C6 model in Wistar rats. Acta Biomaterialia 2008;4:2037-44.

  62. López T, Figueras F, Manjarrez J, Bustos J, Álvarez M, Silvestre- Albero J. Catalytic nanomedicine: a new field in antitumor treatment using supported platinum nanoparticles. In vitro DNA degradation and in vivo tests with C6 animal model on Wistar rats. Eur J Med Chem 2010;45:1982-90.




2020     |     www.medigraphic.com